Ida Ashoori1, 2, Ashok Panigrahy, 13, Arabhi Nagasunder, 14, Girish Dhall5, Marvin D. Nelson1, Stefan Blml1, 2
1Radiology, Childrens Hospital Los Angeles, Los Angeles, CA, United States; 2Rudi Schulte Research Institute, Santa Barbara, CA, United States; 3Pediatric Radiology, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, United States; 4Radiology, Children's Medical Center, Dallas, Dallas, TX, United States; 5Hematology/Oncology, Childrens Hospital Los Angeles, Los Angeles, CA, United States
13C enriched (U-13C) glucose was administered orally to three pediatric brain tumor patients with prominent citrate and to four healthy controls. MR spectra, using a standard PRESS sequence were acquired before and after Glc administration. 13C label replaced 12C and resulted in an apparent reduction of the 1H MRS detectable breakdown products of glucose such as glutamate (Glu) in controls. In patients, citrate, an intermediate of the TCA-cycle, did not accumulate significant label. This is consistent with citrate being not actively involved in glucose metabolism.